Genetic testing to Understand and Address Renal Disease Disparities: The GUARDD Study
In this genomic medicine implementation pilot project, the team conducted a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension. Principal Investigator Carol R. …
Genetic testing to Understand and Address Renal Disease Disparities: The GUARDD Study Read More »